Dental Plaque Accumulation, Gingivitis
Conditions
Brief summary
The goal of this clinical trial is to evaluate the clinical efficacy of an antimicrobial mouthrinse, with a particular focus on its effect on established plaque and the improvement of gum health. Participants will: * Brush and rinse twice a day with the designated products for 6 months * Visit the clinic once every 3 months after baseline for reassessment.
Interventions
OTHERTest Mouthrinse
Test Mouthrinse: 0.0553% NaF (250 ppm Fluoride), Amine and 0.2% Zinc Lactate dihydrate
OTHERControl Mouthrinse
Control Mouthrinse: 0.0553% NaF(250 ppm Fluoride)
Sponsors
Colgate Palmolive
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male and female subjects aged 18-70 years, inclusive. 2. Availability for the 6-month duration of the clinical research study. 3. Good general health based on the opinion of the study investigator. 4. Signed Informed Consent Form. 5. Minimum of 20 natural teeth (excluding third molars). 6. Initial gingivitis index of at least 1.5 as determined by the use of the Loe and Silness Gingival Index. 7. Initial plaque index of at least 1.5 as determined by the use of the Quigley and Hein Plaque Index (Turesky Modification).
Exclusion criteria
1. Be under orthodontic treatment. 2. Presence of partial removable dentures. 3. Tumor(s) of the soft or hard tissues of the oral cavity. 4. Participants with current moderate or severe periodontitis (periodontitis screening index \[PSI\] \>2 in more than 2 sextants or PSI \>3), and/or purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone. 5. Five or more carious lesions requiring immediate restorative treatment. 6. Antibiotic use any time during the one-month period prior to entry into the study. 7. Participation in any other clinical study or test panel within the one month prior to entry into the study. 8. Dental prophylaxis during the past two weeks prior to baseline examinations. 9. History of allergies to oral care/personal care consumer products or their ingredients. 10. On any prescription medicines that might interfere with the study outcome based on the examiner/PI opinion. 11. An existing medical condition that prohibits eating and/or drinking for periods up to 4 hours. 12. History of alcohol and/or drug abuse. 13. Self-reported pregnancy and/or lactating subjects. 14. Subjects with other oral diseases (including gingival hyperplasia, diseases of the oral mucosa), or any condition that the dental examiner considers exclusionary from the study. 15. Smokers or/and users of tobacco products. 16. Enrolled in an undergraduate, postgraduate, or academic dentistry program
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of gum health as measured by the Gingival Index (Löe 1967) between the study groups. | 6-month period | Four areas of the tooth (buccal, lingual, mesial, and distal surfaces) will be assessed. Each site is assigned a score from 0 to 3 based on clinical observation: 0 indicates normal gingiva and 3 denotes severe inflammation with marked redness, edema, ulceration, and a tendency toward spontaneous bleeding. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plaque scores as measured by the Plaque Index (Turesky et al. 1970) between the study groups | 6-month period | The index will quantify dental plaque accumulation by assessing the facial and lingual surfaces of all teeth, typically excluding third molars. Using a disclosing solution to make the bacterial biofilm visible, the examiner will assign a score from 0 to 5 to each surface based on the extent of coverage: 0 indicates no plaque and 5 indicates plaque covering more than two-thirds of the tooth surface. |
Countries
Germany
Contacts
PRINCIPAL_INVESTIGATOREva-Maria Axmann
SGS proderm GmbH
Outcome results
None listed